AR063343A1 - Compuestos para modular c-kit y receptores de pdgfr - Google Patents
Compuestos para modular c-kit y receptores de pdgfrInfo
- Publication number
- AR063343A1 AR063343A1 ARP070104639A ARP070104639A AR063343A1 AR 063343 A1 AR063343 A1 AR 063343A1 AR P070104639 A ARP070104639 A AR P070104639A AR P070104639 A ARP070104639 A AR P070104639A AR 063343 A1 AR063343 A1 AR 063343A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- optionally substituted
- nrc
- alkyl
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Abstract
Son utiles corno inhibidores de cinasa de proteína, así corno métodos para utilizar tales compuestos con el fin de tratar, disminuir, o prevenir una condicion asociada con una actividad de cinasa anormal o mal regulada. En algunas modalidades, proporciona métodos para utilizar tales compuestos con el fin de tratar, disminuir, o prevenir enfermedades o trastornos que involucren una activacion anormal de las cinasas c-kit, PDGFRalfa, PDGFRbeta, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGFbeta, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2beta, BRK, KDR, c-raf o braf, o las formas mutantes de las mismas. Reivindicacion 1: Un compuesto de la formula (1); o sales farmacéuticamente aceptables del mismo, en donde: Y y Z son independientemente CR o N; L es NR-C(O), C(O)NR, C(O)NRC(O)NR, NRC(O)NR, NRC(O)NRC(O), NRC(S)NRCO, NRS(O)0-2 o NRCONRS(O)0-2 y son independientemente halogeno, (CR2)kR6, (CR2)kNR7R8, (CR2)kOR9, (CR2)kSR9, o un alquilo de 1 a 6 átomos de carbono, alquenilo de 2 a 6 átomos de carbono, o alquinilo de 2 a 6 átomos de carbono opcionaImente sustituido; R2 es (CR2)kR6, (CR2)1-4OR9, (CR2)1-4NR7R8, o un alquilo de 1 a 6 átomos de carbono, alquenilo de 2 a 6 átomos de carbono, o alquinilo de 2 a 6 átomos de carbono opcionalmente sustituido; R4 es (CR2)kR6, (CR2)kOR9, o un alquilo de 1 a 6 átomos de carbono, alquenilo de 2 a 6 átomos de carbono, o alquinilo de 2 a 6 átomos de carbono opcionalmente sustituido; R5 es H, halogeno o alquilo de 1 a 6 átomos de carbono; R6 es un cicloalquilo de 3 a 7 átomos de carbono opcionalmente sustituido, o un arilo de 5 a 12 miembros, heterociclo, o heteroarilo opcionalmente sustituido; R7 y R8 son independientemente H, (CR2)kNR7R8, (CR2)kOR9, (CR2)k-R6, o un alquilo de 1 a 6 átomos de carbono, alquenilo de 2 a 6 átomos de carbono, o alquinilo de 2 a 6 átomos de carbono opcionalmente sustituido; o R7 y R8 junto con N en cada NR7R8 pueden formar un anillo opcionalmente sustituido; R9 es H, (CR2)k-R6, o un alquilo de 1 a 6 átomos de carbono, alquenilo de 2 a 6 átomos de carbono, o alquinilo de 2 a 6 átomos de carbono opcionalmente sustituido; cada R es H o alquilo de 1 a 6 átomos de carbono que tiene un átomo de carbono que está opcionalmente sustituido o reemplazado con N, O, =O, S: o dos grupos alquileno en (CR2)k pueden formar un alquenilo o alquinilo; cada alquilo de 1 a 6 átomos de carbono, alquenilo de 2 a 6 átomos de carbono, o alquinilo de 2 a 6 átomos de carbono opcionalmente sustituido, está opcionalmente halogenado u opcionalmente sustituido con N, O o S; k es de 0 a 6; y n es de 0 a 2; en el entendido de que L es C(O)NRC(O)NR, NRC(O)NR, NRC(O)NRC(O), NRC(S)NRCO o NRCONRS(O)0-2 cuando R1 es halogeno (CR2)kNR7R8 o hetero-cicloalquilo de 5 a 8 átomos de carbono y es alquilo de 1 a 6 átomos de carbono.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86243006P | 2006-10-20 | 2006-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063343A1 true AR063343A1 (es) | 2009-01-21 |
Family
ID=39027274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104639A AR063343A1 (es) | 2006-10-20 | 2007-10-19 | Compuestos para modular c-kit y receptores de pdgfr |
Country Status (25)
Country | Link |
---|---|
US (2) | US7678792B2 (es) |
EP (1) | EP2076513A1 (es) |
JP (1) | JP2010506948A (es) |
KR (1) | KR101079520B1 (es) |
CN (1) | CN101528744A (es) |
AR (1) | AR063343A1 (es) |
AU (1) | AU2007309279B2 (es) |
BR (1) | BRPI0718162A2 (es) |
CA (1) | CA2667010A1 (es) |
CL (1) | CL2007003005A1 (es) |
CO (1) | CO6170361A2 (es) |
CR (1) | CR10717A (es) |
EA (1) | EA200900573A1 (es) |
EC (1) | ECSP099353A (es) |
IL (1) | IL197875A0 (es) |
MA (1) | MA30888B1 (es) |
MX (1) | MX2009004141A (es) |
NI (1) | NI200900061A (es) |
NO (1) | NO20091949L (es) |
PE (1) | PE20081262A1 (es) |
SM (1) | SMP200900027B (es) |
TN (1) | TN2009000145A1 (es) |
TW (1) | TW200825081A (es) |
WO (1) | WO2008051757A1 (es) |
ZA (1) | ZA200902711B (es) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7794965B2 (en) | 2002-03-13 | 2010-09-14 | Signum Biosciences, Inc. | Method of identifying modulators of PP2A methylase |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
WO2006084033A1 (en) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
CA2668814A1 (en) | 2006-11-09 | 2008-06-05 | Alcon Research, Ltd. | Water insoluble polymer matrix for drug delivery |
TWI498115B (zh) * | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
WO2009105712A1 (en) * | 2008-02-22 | 2009-08-27 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
EP2282735B1 (en) | 2008-04-21 | 2019-01-16 | Signum Biosciences, Inc. | Pp2a modulators for treating alzheimer, parkinson, diabetes |
FR2930552B1 (fr) * | 2008-04-24 | 2012-10-12 | Centre Nat Rech Scient | N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog |
BRPI0915205A2 (pt) * | 2008-06-11 | 2017-03-21 | Dana Farber Cancer Inst Inc | compostos e composições úteis para o tratamento de malária |
WO2010017331A1 (en) * | 2008-08-05 | 2010-02-11 | George Mason Intellectual Properties, Inc. | Signal pathway alterations and drug target elevations in primary metachronous metastatic colorectal cancer compared to non-metastatic disease |
MX2011004535A (es) * | 2008-10-29 | 2011-11-18 | Deciphera Pharmaceuticals Llc | Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas. |
AR074776A1 (es) * | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
US8674095B2 (en) | 2008-12-19 | 2014-03-18 | Afraxis Holdings, Inc. | Compounds for treating neuropsychiatric conditions |
CA2751517A1 (en) * | 2009-02-13 | 2010-08-19 | Fovea Pharmaceuticals | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
EP2486037A4 (en) | 2009-10-09 | 2013-01-16 | Afraxis Inc | 8-ETHYL-6- (ARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS |
EP2528915B1 (en) | 2010-01-29 | 2015-10-28 | Boehringer Ingelheim International GmbH | Substituted naphthyridines and their use as syk kinase inhibitors |
US9181238B2 (en) | 2010-02-05 | 2015-11-10 | Novartis Ag | N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors |
DK2668210T3 (da) * | 2011-01-26 | 2020-08-24 | Celldex Therapeutics Inc | Anti-kit antistoffer og anvendelser deraf |
ES2625534T3 (es) | 2011-04-25 | 2017-07-19 | Usher Iii Initiative | Pirazolopiridazinas y métodos para el tratamiento de enfermedades degenerativas de la retina y pérdida de la audición asociadas con el síndrome de Usher |
EP2736886B1 (en) * | 2011-07-26 | 2016-09-14 | Boehringer Ingelheim International GmbH | Substituted quinolines and their use as medicaments |
JP2014528412A (ja) * | 2011-09-30 | 2014-10-27 | キネタ・インコーポレイテツド | 抗ウイルス化合物 |
AU2013261128B2 (en) | 2012-05-15 | 2015-11-12 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
PE20210667A1 (es) | 2012-05-15 | 2021-04-05 | Novartis Ag | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 |
CN104302634B (zh) | 2012-05-15 | 2017-02-08 | 诺华股份有限公司 | 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物 |
AU2013261129B2 (en) | 2012-05-15 | 2016-05-12 | Novartis Ag | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
EP2858646B1 (en) * | 2012-06-07 | 2017-12-20 | Deciphera Pharmaceuticals, LLC | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US9334332B2 (en) | 2012-07-25 | 2016-05-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
AU2014302458A1 (en) * | 2013-06-26 | 2015-12-24 | Proteostasis Therapeutics, Inc. | Methods of modulating CFTR activity |
GB201401886D0 (en) | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
US9790219B2 (en) | 2014-03-13 | 2017-10-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
WO2015138934A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
CN113908269A (zh) | 2014-05-23 | 2022-01-11 | 塞尔德克斯医疗公司 | 嗜酸性粒细胞或肥大细胞相关病症的治疗 |
WO2015196071A1 (en) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
CN105085489B (zh) * | 2014-11-05 | 2019-03-01 | 益方生物科技(上海)有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
US10344023B2 (en) | 2014-12-23 | 2019-07-09 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
US10738011B2 (en) | 2014-12-23 | 2020-08-11 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
CA2971850A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
WO2017019589A1 (en) | 2015-07-24 | 2017-02-02 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
CN105664178B (zh) * | 2015-09-24 | 2019-08-20 | 洪健 | Syk作为肝纤维化/硬化治疗靶点的应用 |
SG11201802798WA (en) | 2015-10-06 | 2018-05-30 | Proteostasis Therapeutics Inc | Compounds, compositions, and methods for modulating cftr |
CN107286077B (zh) * | 2016-04-01 | 2021-04-02 | 合肥中科普瑞昇生物医药科技有限公司 | 一种选择性的c-kit激酶抑制剂 |
AU2017248253B2 (en) | 2016-04-07 | 2021-07-29 | Proteostasis Therapeutics, Inc. | Silicone atoms containing ivacaftor analogues |
AU2017280206A1 (en) | 2016-06-21 | 2019-01-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
EP3535243B1 (en) * | 2016-11-04 | 2021-12-15 | Auckland Uniservices Limited | Substituted 9h-xanthen-9-one, 9h-thioxanthen-9-one and acridin-9(10h)-one derivatives and related compounds csf-1r inhibitors for the treatment of cancer |
SG11201908569QA (en) | 2017-03-21 | 2019-10-30 | Arbutus Biopharma Corp | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
EP3621615B1 (en) | 2017-05-12 | 2023-11-15 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
AU2017417160B2 (en) * | 2017-05-30 | 2024-05-02 | Deciphera Pharmaceuticals, Llc | Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha |
CN111094286B (zh) * | 2017-09-20 | 2022-07-29 | 浙江海正药业股份有限公司 | 1,2-二氢-1,6-萘啶类衍生物、其制备方法及其在医药上的用途 |
WO2019058393A1 (en) | 2017-09-22 | 2019-03-28 | Jubilant Biosys Limited | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PAD |
SG11202003463XA (en) | 2017-10-18 | 2020-05-28 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
CN111386265A (zh) | 2017-11-06 | 2020-07-07 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物 |
MX2020005363A (es) | 2017-11-24 | 2020-10-01 | Jubilant Episcribe Llc | Compuestos heterociclicos como inhibidores de prmt5. |
SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
EP3765453A1 (en) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
CA3097982A1 (en) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
US10968199B2 (en) * | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2020052349A1 (zh) * | 2018-09-14 | 2020-03-19 | 上海和誉生物医药科技有限公司 | Fgfr抑制剂、其制备方法和应用 |
WO2020106707A1 (en) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2020112687A2 (en) | 2018-11-26 | 2020-06-04 | Forty Seven, Inc. | Humanized antibodies against c-kit |
US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
BR112022002609A2 (pt) | 2019-08-12 | 2022-08-09 | Deciphera Pharmaceuticals Llc | Métodos de tratamento de tumores estromais gastrointestinais |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
JPWO2021039791A1 (es) * | 2019-08-25 | 2021-03-04 | ||
KR20220123058A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물 |
DK4084778T3 (da) | 2019-12-30 | 2023-12-11 | Deciphera Pharmaceuticals Llc | Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf |
TW202204354A (zh) * | 2020-04-02 | 2022-02-01 | 美商普雷辛肯公司 | 用於csk調節之化合物及方法以及其說明 |
US11912668B2 (en) | 2020-11-18 | 2024-02-27 | Deciphera Pharmaceuticals, Llc | GCN2 and perk kinase inhibitors and methods of use thereof |
CN115108997A (zh) * | 2021-03-22 | 2022-09-27 | 南开大学 | 一类具抑菌活性的磺酰脲类化合物的合成与应用 |
KR20240099221A (ko) * | 2021-09-29 | 2024-06-28 | 리페어 세라퓨틱스 인크. | N-(5-치환된-[(1,3,4-티아다이아졸릴) 또는 (티아졸릴)])(치환된)카복스아마이드 화합물 및 인간 중합효소 세타를 저해하기 위한 이의 용도 |
TW202342055A (zh) | 2022-02-03 | 2023-11-01 | 美商奇奈特生物製藥公司 | Raf激酶抑制劑 |
WO2024039864A1 (en) * | 2022-08-19 | 2024-02-22 | Purdue Research Foundation | Protein:protein interaction inhibitors |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002028853A1 (fr) | 2000-10-02 | 2002-04-11 | Tanabe Seiyaku Co., Ltd. | Compose de benzylamine, son procede de production et produit intermediaire correspondant |
EP1673343A4 (en) * | 2003-10-08 | 2008-09-10 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
AU2005325676A1 (en) | 2004-12-23 | 2006-08-03 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
AU2005321946B2 (en) * | 2004-12-23 | 2012-08-16 | Deciphera Pharmaceuticals, Llc | Enzyme modulators and treatments |
JP2009537520A (ja) | 2006-05-15 | 2009-10-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Fgf受容体キナーゼ阻害剤のための組成物および方法 |
US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
WO2008058126A2 (en) * | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
-
2007
- 2007-10-16 AU AU2007309279A patent/AU2007309279B2/en not_active Ceased
- 2007-10-16 CA CA002667010A patent/CA2667010A1/en not_active Abandoned
- 2007-10-16 BR BRPI0718162-0A patent/BRPI0718162A2/pt not_active IP Right Cessation
- 2007-10-16 KR KR1020097008062A patent/KR101079520B1/ko not_active IP Right Cessation
- 2007-10-16 CN CNA2007800390373A patent/CN101528744A/zh active Pending
- 2007-10-16 JP JP2009533484A patent/JP2010506948A/ja active Pending
- 2007-10-16 US US11/873,196 patent/US7678792B2/en not_active Expired - Fee Related
- 2007-10-16 MX MX2009004141A patent/MX2009004141A/es active IP Right Grant
- 2007-10-16 EP EP07844322A patent/EP2076513A1/en not_active Ceased
- 2007-10-16 WO PCT/US2007/081538 patent/WO2008051757A1/en active Application Filing
- 2007-10-16 EA EA200900573A patent/EA200900573A1/ru unknown
- 2007-10-19 PE PE2007001422A patent/PE20081262A1/es not_active Application Discontinuation
- 2007-10-19 TW TW096139384A patent/TW200825081A/zh unknown
- 2007-10-19 CL CL200703005A patent/CL2007003005A1/es unknown
- 2007-10-19 AR ARP070104639A patent/AR063343A1/es unknown
-
2009
- 2009-03-26 IL IL197875A patent/IL197875A0/en unknown
- 2009-04-16 CR CR10717A patent/CR10717A/es not_active Application Discontinuation
- 2009-04-17 TN TNP2009000145A patent/TN2009000145A1/fr unknown
- 2009-04-17 CO CO09039151A patent/CO6170361A2/es not_active Application Discontinuation
- 2009-04-20 SM SM200900027T patent/SMP200900027B/it unknown
- 2009-04-20 NI NI200900061A patent/NI200900061A/es unknown
- 2009-04-20 ZA ZA200902711A patent/ZA200902711B/xx unknown
- 2009-05-13 MA MA31869A patent/MA30888B1/fr unknown
- 2009-05-19 NO NO20091949A patent/NO20091949L/no not_active Application Discontinuation
- 2009-05-20 EC EC2009009353A patent/ECSP099353A/es unknown
- 2009-12-02 US US12/629,665 patent/US8106068B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8106068B2 (en) | 2012-01-31 |
IL197875A0 (en) | 2009-12-24 |
ZA200902711B (en) | 2010-05-26 |
MX2009004141A (es) | 2009-05-01 |
SMP200900027B (it) | 2010-01-19 |
MA30888B1 (fr) | 2009-11-02 |
CR10717A (es) | 2009-07-02 |
JP2010506948A (ja) | 2010-03-04 |
SMAP200900027A (it) | 2009-07-14 |
CA2667010A1 (en) | 2008-05-02 |
CN101528744A (zh) | 2009-09-09 |
ECSP099353A (es) | 2009-06-30 |
TN2009000145A1 (en) | 2010-10-18 |
AU2007309279B2 (en) | 2011-03-24 |
NO20091949L (no) | 2009-05-19 |
CO6170361A2 (es) | 2010-06-18 |
EP2076513A1 (en) | 2009-07-08 |
PE20081262A1 (es) | 2008-10-29 |
KR20090054477A (ko) | 2009-05-29 |
TW200825081A (en) | 2008-06-16 |
NI200900061A (es) | 2010-03-10 |
US7678792B2 (en) | 2010-03-16 |
US20100081656A1 (en) | 2010-04-01 |
CL2007003005A1 (es) | 2008-05-23 |
US20080176846A1 (en) | 2008-07-24 |
BRPI0718162A2 (pt) | 2013-11-26 |
KR101079520B1 (ko) | 2011-11-03 |
EA200900573A1 (ru) | 2009-10-30 |
AU2007309279A1 (en) | 2008-05-02 |
WO2008051757A1 (en) | 2008-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR063343A1 (es) | Compuestos para modular c-kit y receptores de pdgfr | |
ECSP10010044A (es) | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
EA201000325A1 (ru) | Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ | |
Chahrour et al. | Small molecule kinase inhibitors as anti-cancer therapeutics | |
PE20080828A1 (es) | Compuestos y composiciones como inhibidores de la quinasa proteica | |
AR056346A1 (es) | Compuestos y composiciones como inhibidores de quinasa de proteina | |
EA201000130A1 (ru) | Бициклические гетероарильные соединения и их применение в качестве ингибиторов киназы | |
EA200901608A1 (ru) | Производные хинаксолина в качестве ингибиторов тирозинкиназной активности киназ janus | |
EA201000003A1 (ru) | Ингибиторы протеинкиназ и способы их применения | |
BRPI0415210A (pt) | compostos e composições como inibidores de proteìna cinase | |
ECSP077985A (es) | Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina | |
CY1113642T1 (el) | Γεφυρωμενες δικυκλικες ετεροαρυλ υποκατεστημενες τριαζολες, χρησιμες ως αναστολεις της axl | |
EA200801001A1 (ru) | Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине | |
EA201001331A1 (ru) | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR | |
PE20091116A1 (es) | Derivados de piridina y pirazina como inhibidores de tirosina quinasas | |
CR7880A (es) | Derivados sustituidos de pirrolo-pirazol como inhibidores de quinasa | |
DE602007007985D1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyrimidine | |
EA201490542A1 (ru) | Соединения и композиции в качестве pdgfr киназных ингибиторов | |
PE20140927A1 (es) | Compuestos heterociclicos como inhibidores de cinasas | |
AR046119A1 (es) | Pirimidinas sustituidas con sulfoximina como inhibidores de cdk y / o vegf su preparacion y sus usos como medicamento | |
DK1791830T3 (da) | Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer | |
DE602006009968D1 (de) | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten | |
ECSP109953A (es) | Derivados de piridazinona | |
PE20110405A1 (es) | Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion | |
EA200800018A1 (ru) | Аминопиримидины в качестве модуляторов киназы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |